FDA approved Vidaza (azacitidine) for pediatric patients with newly diagnosed juvenile myelomonocytic leukemia.
FDA granted marketing authorization to the Parsortix System for the harvesting of circulating cancer tumor cells in metastatic breast cancer.
FDA approved a combination of Tibsovo (ivosidenib) and Vidaza (azacitidine) for the treatment of patients with newly diagnosed IDH1-mutant acute myeloid leukemia who are 75 years or older or with comorbidities that prevent the use of induction chemotherapy.
An analysis conducted by Friends of Cancer Research showed that the FDA Breakthrough Therapy Designation criteria select drugs that lead to better outcomes for patients with lung cancer.
A committee of the European Medicines Agency recommended the approval for expanded use of Keytruda (pembrolizumab) as a standalone therapy for the adjuvant treatment of adults and adolescents aged 12 years and older with stage IIB or IIC melanoma who have undergone complete resection.
Case Western Reserve University signed an exclusive license agreement with Picture Health to develop AI technologies to help predict, diagnose, and treat lung cancer.
AmerisourceBergen launched Clinical Trial Navigator, a solution suite that supports biopharmaceutical clinical trial recruitment within community-based specialty practices.
Fox Chase Cancer Center used to be a place where Nobel laureates toiled. Now, people who love the place—and in oncology, many people do—are hoping that Jonathan Chernoff, Fox Chase’s new director, will restore vitality to the venerable Philadelphia-based cancer center.
Hospitals and radiology clinics are rationing—of all things—intravenous contrast agents used for computed tomography imaging.
The Union for International Cancer Control and multiple partners are establishing the Access to Oncology Medicines Coalition, a global partnership to increase access to quality-assured essential cancer medicines in low- and lower-middle-income countries, and to help countries develop the capacity for their proper use.
